Published in

Wiley, Pediatric Blood & Cancer, 10(69), 2022

DOI: 10.1002/pbc.29882

Links

Tools

Export citation

Search in Google Scholar

Epithelioid hemangioendothelioma in children: The European Pediatric Soft Tissue Sarcoma Study Group experience

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractThe European pediatric Soft tissue sarcoma Study Group analyzed all children with epithelioid hemangioendothelioma prospectively registered in the NRSTS‐05 (EUDRACT 2005‐001139‐31) and in MTS‐2008 (NCT00379457) studies: 10 patients with localized and one with metastatic disease. Median age was 14.3 years (range, 9.0–18.8). Local therapy was initial primary surgery in seven cases, and five patients received systemic therapy. No patients received radiotherapy. After a median follow‐up of 50 months (range, 6–176) for living patients, nine patients remain alive off therapy and two died. Five‐year progression free and overall survivals are, respectively, 77.1% (95% confidence interval [CI]: 34.5–93.9) and 74.1% (95% CI: 28.1–93.0).